PDI Moves into MDx Space with Acquisition of Two Asuragen microRNA Tests | GenomeWeb

NEW YORK (GenomeWeb) – PDI said after the close of the market Wednesday that its Interpace Diagnostics subsidiary will enter the molecular diagnostics market through the acquisition of two tests from Asuragen.

PDI said that it will pay Asuragen $8 million upfront in cash, future commercial milestone-based payments, and royalties for the miRInform Thyroid and Pancreas cancer tests, IP related to the tests and other tests in development for thyroid cancer, as well as a tissue sample biobank containing more than 5,000 samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.